Design and synthesis of novel dual-cyclic RGD peptides for αvβ3 integrin targeting

Bioorg Med Chem Lett. 2019 Apr 1;29(7):896-900. doi: 10.1016/j.bmcl.2019.01.043. Epub 2019 Feb 1.

Abstract

The specific binding of RGD cyclic peptide with integrin αvβ3 attracts great research interest for tumor-targeting drug delivery. Herein, we designed and synthesized a series of dual-ring RGD-peptide derivatives as a drug carrier for αvβ3 targeting. Three novel peptides showed excellent cell adhesion inhibition effect, in which, P3 exhibited 7-fold enhancement in IC50 compared with cyclo(RGDfK). Drug-loaded cytotoxicity experiment and imaging experiment indicated that such dual-cyclic RGD peptides have good tumor targeting effects. This work provides a new strategy for the design of novel RGD peptides.

Keywords: Adhesion inhibition; Cyclo(RGDfK); RGD cyclic peptide; Tumor-targeting; α(v)β(3) integrin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Cell Adhesion / drug effects
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Drug Design
  • Humans
  • Integrin alphaVbeta3 / metabolism*
  • Oligopeptides / chemical synthesis*
  • Oligopeptides / chemistry
  • Oligopeptides / pharmacology*
  • Protein Conformation

Substances

  • Antineoplastic Agents
  • Integrin alphaVbeta3
  • Oligopeptides
  • arginyl-glycyl-aspartic acid